KR102450020B1 - 약물 전달 및 전안부 보호를 위한 안구용 제제 - Google Patents

약물 전달 및 전안부 보호를 위한 안구용 제제 Download PDF

Info

Publication number
KR102450020B1
KR102450020B1 KR1020177010289A KR20177010289A KR102450020B1 KR 102450020 B1 KR102450020 B1 KR 102450020B1 KR 1020177010289 A KR1020177010289 A KR 1020177010289A KR 20177010289 A KR20177010289 A KR 20177010289A KR 102450020 B1 KR102450020 B1 KR 102450020B1
Authority
KR
South Korea
Prior art keywords
active agent
months
compound
days
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177010289A
Other languages
English (en)
Korean (ko)
Other versions
KR20170058976A (ko
Inventor
데이비드 피 빙거먼
폴 쥐 체니
마틴 비 왁스
Original Assignee
팬옵티카, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 팬옵티카, 인크. filed Critical 팬옵티카, 인크.
Priority to KR1020227033489A priority Critical patent/KR102555091B1/ko
Publication of KR20170058976A publication Critical patent/KR20170058976A/ko
Application granted granted Critical
Publication of KR102450020B1 publication Critical patent/KR102450020B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177010289A 2014-09-17 2015-09-17 약물 전달 및 전안부 보호를 위한 안구용 제제 Active KR102450020B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227033489A KR102555091B1 (ko) 2014-09-17 2015-09-17 약물 전달 및 전안부 보호를 위한 안구용 제제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17
US62/051,794 2014-09-17
PCT/US2015/050818 WO2016044671A1 (en) 2014-09-17 2015-09-17 Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033489A Division KR102555091B1 (ko) 2014-09-17 2015-09-17 약물 전달 및 전안부 보호를 위한 안구용 제제

Publications (2)

Publication Number Publication Date
KR20170058976A KR20170058976A (ko) 2017-05-29
KR102450020B1 true KR102450020B1 (ko) 2022-09-30

Family

ID=55453708

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177010289A Active KR102450020B1 (ko) 2014-09-17 2015-09-17 약물 전달 및 전안부 보호를 위한 안구용 제제
KR1020227033489A Active KR102555091B1 (ko) 2014-09-17 2015-09-17 약물 전달 및 전안부 보호를 위한 안구용 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227033489A Active KR102555091B1 (ko) 2014-09-17 2015-09-17 약물 전달 및 전안부 보호를 위한 안구용 제제

Country Status (19)

Country Link
US (6) US9814702B2 (enExample)
EP (2) EP3878449B1 (enExample)
JP (3) JP6657193B2 (enExample)
KR (2) KR102450020B1 (enExample)
CN (2) CN113209000B (enExample)
AU (2) AU2015317531B2 (enExample)
CA (1) CA2958315A1 (enExample)
DK (1) DK3193867T3 (enExample)
ES (2) ES3010497T3 (enExample)
HU (1) HUE053852T2 (enExample)
IL (2) IL282504B (enExample)
MA (1) MA56220A (enExample)
MX (2) MX383792B (enExample)
NZ (1) NZ767710A (enExample)
PL (1) PL3193867T3 (enExample)
PT (1) PT3193867T (enExample)
RU (2) RU2704810C2 (enExample)
WO (1) WO2016044671A1 (enExample)
ZA (1) ZA201701303B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
SG11201907400YA (en) * 2018-07-18 2020-02-27 Univ Wenzhou Medical Method for treating myopia and application in preparation of medicament
EP3870204A4 (en) * 2018-10-24 2022-12-21 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics formulations
JP2022131565A (ja) * 2021-02-26 2022-09-07 ロート製薬株式会社 水性医薬組成物
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
WO2013126799A1 (en) 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
WO2014152661A1 (en) 2013-03-14 2014-09-25 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053806A1 (en) * 1997-05-26 1998-12-03 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
YU36403A (sh) * 2000-11-28 2006-08-17 Pfizer Products Inc. Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
RU2012105453A (ru) 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
EP2482677A1 (en) * 2009-09-30 2012-08-08 The Regents of The University of California Cofactors and methods for use for individuals
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP5956992B2 (ja) * 2010-08-17 2016-07-27 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． スクアラミンの眼用製剤
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
WO2013126799A1 (en) 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
WO2014152661A1 (en) 2013-03-14 2014-09-25 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye

Also Published As

Publication number Publication date
PT3193867T (pt) 2021-03-09
JP6657193B2 (ja) 2020-03-04
RU2017112930A (ru) 2018-10-17
CA2958315A1 (en) 2016-03-24
EP3193867A1 (en) 2017-07-26
ES3010497T3 (en) 2025-04-03
IL282504B (en) 2022-08-01
EP3193867A4 (en) 2018-05-02
MX2017003436A (es) 2017-07-28
MX383792B (es) 2025-03-14
US20160206599A1 (en) 2016-07-21
BR112017005523A2 (pt) 2017-12-05
CN113209000A (zh) 2021-08-06
MA56220A (fr) 2022-04-20
IL282504A (en) 2021-06-30
JP2021121624A (ja) 2021-08-26
ES2863601T3 (es) 2021-10-11
HUE053852T2 (hu) 2021-07-28
US20210275501A1 (en) 2021-09-09
DK3193867T3 (da) 2021-04-06
US20190314343A1 (en) 2019-10-17
PL3193867T3 (pl) 2021-07-12
RU2017112930A3 (enExample) 2019-04-11
KR20220137157A (ko) 2022-10-11
EP3878449A1 (en) 2021-09-15
US9814702B2 (en) 2017-11-14
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
JP7176042B2 (ja) 2022-11-21
JP2020079274A (ja) 2020-05-28
MX2021006070A (es) 2021-07-06
WO2016044671A1 (en) 2016-03-24
JP2017527600A (ja) 2017-09-21
AU2015317531B2 (en) 2020-11-19
CN113209000B (zh) 2025-05-13
JP6890692B2 (ja) 2021-06-18
AU2021200997A1 (en) 2021-03-11
US10183014B2 (en) 2019-01-22
US20160074371A1 (en) 2016-03-17
IL251019B (en) 2021-05-31
US20240277674A1 (en) 2024-08-22
IL251019A0 (en) 2017-04-30
RU2704810C2 (ru) 2019-10-31
ZA201701303B (en) 2021-07-28
EP3193867B1 (en) 2021-01-20
US9623011B2 (en) 2017-04-18
NZ729142A (en) 2023-08-25
RU2768652C1 (ru) 2022-03-24
KR102555091B1 (ko) 2023-07-13
CN106999476A (zh) 2017-08-01
US20180078531A1 (en) 2018-03-22
NZ767710A (en) 2023-09-29
CN106999476B (zh) 2021-05-04
EP3878449B1 (en) 2024-10-30
KR20170058976A (ko) 2017-05-29

Similar Documents

Publication Publication Date Title
CN105142686B (zh) 给药于眼后段的眼用制剂
JP7176042B2 (ja) 薬物送達および前眼部保護のための眼用製剤
HK40059709A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK40060903B (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK40060903A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK1236824B (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK1236824A1 (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
NZ729142B2 (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170414

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200915

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220111

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220629

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220926

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220928

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220928

End annual number: 3

Start annual number: 1

PG1601 Publication of registration